GNFT targets scalable non-invasive MASH diagnosis, ~$1.5B market by 2033
Genfit says a scalable, non-invasive diagnostic for at-risk MASH could unlock an annual lab market of about $1.5B by 2033. It highlights moving from LDT to IVD and expanding payer coverage.